Document:

Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2018, by and between MyDx, Inc., a Nevada
corporation, with headquarters located at 6335 Ferris Square, Suite B, San Diego, CA 92121 (the “Company”) and GS
CAPITAL PARTNERS, LLC, with its address at 30 Broad Street, Suite 1201, New York, NY 10004 (the “Buyer”).

 

WHEREAS:

 

A. The Company and
the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the
rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the
Securities Act of 1933, as amended (the “1933 Act”);

 

B. Buyer desires to
purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement an 8% convertible
note of the Company, in the form attached hereto as Exhibit A in the aggregate principal amount of $82,000.00 (together with any
note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof,
the “Note”), convertible into shares of common stock, of the Company (the “Common Stock”), upon the terms
and subject to the limitations and conditions set forth in such Note. The Note shall contain an OID of $2,000 such that the purchase
price shall be $80,000.00. The Note shall be paid for by the Buyer as set forth herein.

 

C. The Buyer wishes
to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Note as is set forth immediately
below its name on the signature pages hereto; and

 

NOW THEREFORE,
the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1. Purchase and Sale
of Note.

 

a. Purchase of Note.
On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the
Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages hereto.

  

     

     

    

 

b. Form of Payment.
On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued and sold to it at
the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company,
in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal
to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the
Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price.

 

c. Closing Date.
The date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be on
or around December 19, 2018.

 

2. Buyer’s Representations
and Warranties. The Buyer represents and warrants to the Company that:

 

a. Investment Purpose.
As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise
pursuant to the Note, such shares of Common Stock being collectively referred to herein as the “Conversion Shares”
and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public
sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; provided,
however, that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum
or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration
statement or an exemption under the 1933 Act.

 

b. Accredited Investor
Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited
Investor”). Any of Buyer’s transferees, assignees, or purchasers must be “accredited investors” in order
to qualify as prospective transferees, permitted assignees in the case of Buyer’s or Holder’s transfer, assignment
or sale of the Note.

 

c. Reliance on Exemptions.
The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration
requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of,
and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer
set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

 

d. Information.
The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with
all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of
the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so
long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding
the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information
unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries
nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect
Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands
that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute
a breach of any of the Company’s representations and warranties made herein.

 

    2

     

    

 

e. Governmental
Review. The Buyer understands that no United States federal or state agency or any other government or governmental agency
has passed upon or made any recommendation or endorsement of the Securities.

 

f. Transfer or Re-sale.
The Buyer understands that (i) the sale or re-sale of the Securities has not been and is not being registered under the 1933 Act
or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold pursuant
to an effective registration statement under the 1933 Act, (b) in the case of subparagraphs (c), (d) and (e) below, the Buyer
shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance and scope
customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be
sold, or transferred pursuant to an exemption from such registration, including the removal of any restrictive legend which opinion
shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined in
Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”) of the Buyer who agrees to sell or otherwise
transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the Securities are
sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule)
(“Regulation S”), (e) such transfer is effectuated on or after the Conversion Date; (ii) any sale of such Securities
made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable,
any re-sale of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed
to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933
Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation
to register such Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption
thereunder (in each case). Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may
be pledged as collateral in connection with a bona fide margin account or other lending arrangement.

 

g. Legends.
The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act will
be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that
can then be immediately sold, the Conversion Shares may bear a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of the certificates for such Securities):

 

“NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE
FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.”

 

    3

     

    

 

The legend set forth
above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it
is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an
effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without
any restriction as to the number of securities as of a particular date that can then be immediately sold, and (b) such holder provides
the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions,
to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, and that legend
removal is appropriate, which opinion shall be accepted by the Company so that the sale or transfer is effected. The Buyer agrees
to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with
applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided
by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation
S, within 2 business days, it will be considered an Event of Default under the Note.

 

h. Authorization;
Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered on behalf
of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

 

i. Residency.
The Buyer is a resident of the jurisdiction set forth immediately below the Buyer’s name on the signature pages hereto.

 

j. No Short Sales. Buyer/Holder, its
successors and assigns, agree that so long as the Note remains outstanding, the Buyer/Holder and any of its affiliates shall not
enter into or effect “short sales” of the Common Stock or hedging transaction which establishes a short position with
respect to the Common Stock of the Company. The Company acknowledges and agrees that upon delivery of a Conversion Notice by the
Buyer/Holder, the Buyer/Holder immediately owns the shares of Common Stock described in the Conversion Notice and any sale of those
shares issuable under such Conversion Notice would not be considered short sales.

 

    4

     

    

 

3. Representations
and Warranties of the Company. The Company represents and warrants to the Buyer that:

 

a. Organization
and Qualification. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and
in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other)
to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.

 

b. Authorization;
Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the
Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms
hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the
transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation
for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s
Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required,
(iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized
representative is the true and official representative with authority to sign this Agreement and the other documents executed in
connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the
Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable
against the Company in accordance with its terms.

 

c. Issuance of Shares.
The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance with its respective
terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect
to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will
not impose personal liability upon the holder thereof.

 

d. Acknowledgment
of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance
of the Conversion Shares upon conversion of the Note. The Company further acknowledges that its obligation to issue Conversion
Shares upon conversion of the Note in accordance with this Agreement, the Note is absolute and unconditional regardless of the
dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

 

    5

     

    

 

e. No Conflicts.
The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares)
will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate
or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of
time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse Effect). All consents, authorizations, orders, filings and registrations
which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date
hereof. The Company is not in violation of the listing requirements of the OTC Markets Exchange (the “OTC MARKETS”)
and does not reasonably anticipate that the Common Stock will be delisted by the OTC MARKETS in the foreseeable future, nor are
the Company’s securities “chilled” by FINRA. The Company and its Subsidiaries are unaware of any facts or circumstances
which might give rise to any of the foregoing.

 

f. Absence of Litigation.
Except as disclosed in the Company’s Periodic Report filings with the SEC, there is no action, suit, claim, proceeding, inquiry
or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the
knowledge of the Company or any of its subsidiaries, threatened against or affecting the Company or any of its subsidiaries, or
their officers or directors in their capacity as such, that could have a material adverse effect. Schedule 3(f) contains a complete
list and summary description of any pending or, to the knowledge of the Company, threatened proceeding against or affecting the
Company or any of its subsidiaries, without regard to whether it would have a material adverse effect. The Company and its subsidiaries
are unaware of any facts or circumstances which might give rise to any of the foregoing.

 

g. Acknowledgment
Regarding Buyer’ Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting solely in the capacity
of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges
that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this
Agreement and the transactions contemplated hereby and any statement made by the Buyer or any of its respective representatives
or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely
incidental to the Buyer’ purchase of the Securities. The Company further represents to the Buyer that the Company’s
decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

 

    6

     

    

 

h. No Integrated
Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly
made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration
under the 1933 Act of the issuance of the Securities to the Buyer.

 

i. Title to Property.
The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title
to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case free
and clear of all liens, encumbrances and defects except such as are described in Schedule 3(i) or such as would not have a material
adverse effect. Any real property and facilities held under lease by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as would not have a material adverse effect.

 

j. Bad Actor.
No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act as amended on the basis of
being a “bad actor” as that term is established in the September 19, 2013 Small Entity Compliance Guide published
by the Securities and Exchange Commission.

 

k. Breach of Representations
and Warranties by the Company. If the Company breaches any of the representations or warranties set forth in this Section 3,
and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default
under the Note.

 

4. COVENANTS.

 

a. Expenses.
At the Closing, the Company shall reimburse Buyer for expenses incurred by them in connection with the negotiation, preparation,
execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith (“Documents”),
including, without limitation, reasonable attorneys’ and consultants’ fees and expenses, transfer agent fees, fees
for stock quotation services, fees relating to any amendments or modifications of the Documents or any consents or waivers of provisions
in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of restructuring the transactions contemplated
by the Documents. When possible, the Company must pay these fees directly, otherwise the Company must make immediate payment for
reimbursement to the Buyer for all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice
by the Buyer.

 

b. Listing.
The Company shall promptly secure the listing of the Conversion Shares upon each national securities exchange or automated quotation
system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as the
Buyer owns any of the Note Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing
of all Conversion Shares from time to time issuable upon conversion of the Note. The Company will obtain and, so long as the Buyer
owns any of the Securities, maintain the listing and trading of its Common Stock on the OTC MARKETS or any equivalent replacement
market, the Nasdaq stock market (“Nasdaq”), or the New York Stock Exchange (“NYSE) and will comply in all respects
with the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory
Authority (“FINRA”) and such exchanges, as applicable. The Company shall promptly provide to the Buyer copies of any
notices it receives from the OTC MARKETS and any other markets on which the Common Stock is then listed regarding the continued
eligibility of the Common Stock for listing on such markets.

 

    7

     

    

 

c. Corporate Existence.
So long as the Buyer beneficially owns the Note, the Company shall maintain its corporate existence and shall not sell all or substantially
all of the Company’s assets, except in the event of a merger or consolidation or sale of all or substantially all of the
Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations
hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded corporation
whose Common Stock is listed for trading on the OTC MARKETS, Nasdaq or NYSE.

 

d. No Integration.
The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that would require
registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities to be
integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable
to the Company or its securities.

 

e. Breach of Covenants.
If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the
Buyer pursuant to this Agreement, it will be considered an event of default under the Note.

 

5. Governing
Law; Miscellaneous.

 

a. Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles
of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Agreement
shall be brought only in the state courts of New York or in the federal courts located in the state and county of New York. The
parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and
shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company and
Buyer waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees
and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

    8

     

    

 

b. Counterparts;
Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original
but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each
party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party hereto by
facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

c. Headings.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of,
this Agreement.

 

d. Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

e. Entire Agreement;
Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect
to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the
Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement
may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

 

f. Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, (iv) via electronic
mail or (v) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such
party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given
hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business
hours where such notice is to be received) or delivery via electronic mail, or the first business day following such delivery (if
delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business
day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt
of such mailing, whichever shall first occur. The addresses for such communications shall be:

 

If to the
Company, to:

 

MyDx, Inc.

6335 Ferris
Square, Suite B

San Diego,
CA 92121

Attn: Matthew
Bucciero, CEO

 

    9

     

    

 

If to the Buyer:

 

GS CAPITAL PARTNERS, LLC

30 Broad
Street, Suite 1201

New York,
NY 10004

Attn: Gabe
Sayegh

 

Each party shall provide
notice to the other party of any change in address.

 

g. Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Neither
the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent
of the other. Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any “qualified person”, any
“permitted assigns”, or “prospective transferee” that acquires or purchases Note Securities in a private
transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent
of the Company with Buyer’s Opinion of Counsel. A qualified person is an “accredited investor” transferee, assignee,
or purchaser of the Note who succeeds to the Holder’s right, title and interest to all or a portion of the Note accompanied
with an Opinion of Counsel as provided for in Section 2(f).

 

h. Third Party Beneficiaries.
This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is
not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

i. Survival.
The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the
closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees to
indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result
of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth
in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

j. Further Assurances.
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

k. No Strict Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and
no rules of strict construction will be applied against any party.

 

l. Remedies. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of
the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations
under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions
of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition
to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement
and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond
or other security being required.

 

    10

     

    

 

IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above
written.

 

	MYDX, INC.	 
	 	 	 
	By:	 	 
	Name:	Matthew Bucciero, CEO	 
	 	 	 
	GS CAPITAL PARTNERS, LLC.	 
	 	 	 
	By:	 	 
	Name: 	Gabe Sayegh	 
	Title:	Manager	 

 

	AGGREGATE SUBSCRIPTION AMOUNT:	 	$	82,000.00	 
	 	 	 	 	 
	Aggregate Principal Amount of Note:	 	 	 	 
	 	 	 	 	 
	Aggregate Purchase Price:	 	 	 	 

 

Note 1: $82,000,000.00 less $2,000.00 in
OID, less $4,000.00 in legal fees.

 

    11

     

    

 

EXHIBIT A

NOTE 1- $82,000.00

 

    12exhibit102fourthsuppleme

                                                                                                                                                                                                    MISSISSIPPI BUSINESS FINANCE CORPORATION                                    to                  U.S. BANK NATIONAL ASSOCIATION             (successor to Deutsche Bank National Trust Company),                                as Trustee                                        FOURTH SUPPLEMENTAL TRUST INDENTURE                    Dated effective as of September 28, 2018                                                                     Relating to:                     Mississippi Business Finance Corporation           Taxable Industrial Development Revenue Bonds, Series 2013                   (Helen of Troy Olive Branch, MS Project)                                                       

 

       FOURTH SUPPLEMENTAL TRUST INDENTURE dated effective as of September 28,   2018  (the  “Supplemental  Indenture”)  between  the  MISSISSIPPI  BUSINESS  FINANCE   CORPORATION,  a  public  corporation  duly  created  and  validly  existing  pursuant  to  the   Constitution and laws of the State of Mississippi (the “Issuer”), and U.S. BANK NATIONAL   ASSOCIATION  (successor  to  Deutsche  Bank  National  Trust  Company),  Olive  Branch,   Mississippi,  a  national  banking  association  duly  organized  and existing  under  the  laws  of  the   United  States  of  America,  as  trustee  (the  “Trustee”),  evidencing  the  agreement  of  the  parties   hereto.                                      RECITALS          WHEREAS, the Issuer and the Trustee are parties to that certain Trust Indenture dated as   of March 1, 2013, as supplemented by that certain First Supplemental Trust Indenture, dated as   of March 1, 2014, and that certain Second Supplemental Trust Indenture dated as of February 18,   2015 but effective as of February 1, 2015 and that certain Third Supplemental Trust Indenture   dated as of December 7, 2016 but effective as of December 1, 2016 (said Trust Indenture, as   supplemented, the “Indenture”) relating to the issuance of the $38,000,000 maximum aggregate   principal amount of Mississippi Business Finance Corporation Taxable Industrial Development   Revenue Bonds, Series 2013 (Helen of Troy Olive Branch, MS Project), dated as of March 20,   2013 (the “Bonds”);          WHEREAS, each of the Issuer and the Trustee have been directed by Kaz USA, Inc., a   Massachusetts corporation (the “Company”), and Bank of America, N.A. (the “Purchaser”) to   amend the Indenture pursuant to this Supplemental Indenture as provided herein;          WHEREAS,  in  furtherance  of  the  foregoing,  each  of  the  Issuer  and  the  Trustee  have   agreed to amend the applicable provisions of the Indenture to the extent specified below upon   the terms and conditions set forth below.          NOW,  THEREFORE,  in  consideration  of  the  agreements  hereinafter contained,  the  parties hereto agree as follows:         Section 1.   Definitions.  Capitalized terms used herein and not otherwise defined shall   have the respective meanings ascribed thereto in the Indenture.          Section 2.  Amendments to the Indenture.            (a)   Section  1.1  of  the  Indenture  is  hereby  amended  by  adding  the  defined  terms  thereto in proper alphabetical order to read as follows:               “LIBOR Screen Rate” means the LIBOR quote on the applicable screen         page the Purchaser designates to determine LIBOR (or such other commercially         available source providing such quotations as may be designated by the Purchaser         from time to time).                “LIBOR Successor Rate” has the meaning specified in Section 9.7.                                           1  

 

            “LIBOR Successor Rate Conforming Changes” means, with respect to any        proposed  LIBOR  Successor  Rate,  any  conforming  changes  to  the  definition  of        Base Rate, Interest Period, timing and frequency of determining rates and making        payments of interest and other administrative matters as may be appropriate, in        the discretion of the Purchaser, to reflect the adoption of such LIBOR Successor        Rate  and  to  permit  the  administration  thereof  by  the  Purchaser in a manner        substantially consistent with market practice (or, if the Purchaser determines that        adoption of any portion of such market practice is not administratively feasible or        that  no  market  practice  for  the  administration  of  such  LIBOR  Successor  Rate        exists,  in  such  other  manner  of  administration  as  the  Purchaser  determines  in        consultation with the Company).               “Scheduled  Unavailability  Date”  has  the  meaning  specified  in        Section 14.10.         (b)   The  definition  of  “Eurodollar  Rate”  set  forth  in  Section 1.1  of  the  Indenture  is  hereby amended to read as follows:               “Eurodollar Rate” means:               (a)  for any Interest Period with respect to a Eurodollar Rate Loan, the        rate  per  annum  equal  to  the  London  Interbank  Offered  Rate  (“LIBOR”)  or  a        comparable  or  successor  rate,  which  rate  is  approved  by  the  Purchaser,  as        published by Bloomberg (or such other commercially available source providing        such  quotations  as  may  be  designated  by  the  Purchaser  from  time  to  time)  at        approximately 11:00 a.m., London time, two London Banking Days prior to the        commencement of such Interest Period, for Dollar deposits (for delivery on the        first day of such Interest Period) with a term equivalent to such Interest Period;        and               (b)  for  any  interest  calculation  with  respect  to  a  Base  Rate  Loan  on        any  date,  the  rate  per  annum  equal  to  LIBOR,  at  approximately  11:00  a.m.,        London time, determined two London Banking Days prior to such date for Dollar        deposits with a term of one month commencing that day;               provided  that  (A)  notwithstanding  anything  to  the  contrary  above,  if        LIBOR shall be less than zero, then the Eurodollar Rate shall be deemed to be        zero for purposes of this Indenture and (b) to the extent a comparable or successor        rate  is  approved  by  the  Purchaser  in  connection  with  any  rate  set  forth  in  this        definition, the approved rate shall be applied in a manner consistent with market        practice;  provided,  further  that  to  the  extent  such  market  practice  is  not        administratively feasible for the Purchaser, such approved rate shall be applied in        a manner as otherwise reasonably determined by the Purchaser.                                          2  

 

      (c)   The definition of “Federal Funds Rate” set forth in Section 1.1 of the Indenture is  hereby amended to read as follows:               “Federal Funds Rate” means, for any day, the rate per annum equal to the        weighted  average  of  the  rates  on  overnight  Federal  funds  transactions  with        members  of  the  Federal  Reserve  System  arranged  by  Federal  funds  brokers  on        such day, as published by the Federal Reserve Bank of New York on the Business        Day  next  succeeding  such  day;  provided  that  (a)  if  such  day  is not  a  Business        Day, the Federal Funds Rate for such day shall be such rate on such transactions        on  the  next  preceding  Business  Day  as  so  published  on  the  next succeeding        Business  Day,  and  (b)  if  no  such  rate  is  so  published  on  such  next  succeeding        Business  Day,  the  Federal  Funds  Rate  for  such  day  shall  be  the average  rate        (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) charged to        Bank  of  America  on  such  day  on  such  transactions  as  determined by  the        Purchaser; provided further, that, if the Federal Funds Rate shall be less than zero,        such rate shall be deemed to be zero for purposes of this Indenture.         (d)   Article  XIV  of  the  Indenture  is  hereby  amended  to  add  a  new  Section  14.10  thereto to read as follows:               Section 14.10 LIBOR  Successor  Rate.    Notwithstanding  anything  to  the       contrary  in  this  Indenture,  if  the  Purchaser  determines  (which determination  shall  be       conclusive absent manifest error) that:              (a)   adequate  and  reasonable  means do not exist for ascertaining LIBOR  for       any requested Interest Period, including, without limitation, because the LIBOR Screen       Rate is not available or published on a current basis and such circumstances are unlikely       to be temporary; or              (b)   the administrator of the LIBOR Screen Rate or a Governmental Authority       having jurisdiction over the Purchaser has made a public statement identifying a specific       date after which LIBOR or the LIBOR Screen Rate shall no longer be made available, or       used  for  determining  the  interest  rate  of  loans  (such  specific date,  the  “Scheduled        Unavailability Date”),          then,  reasonably  promptly  after  such  determination  by  the  Purchaser  or  receipt  by  the  Purchaser of such notice, as applicable, the Purchaser and the Company shall endeavor to cause  the amendment of this Indenture to replace LIBOR with an alternate benchmark rate (including  any mathematical or other adjustments to the benchmark (if any) incorporated therein) (any such  proposed rate, a “LIBOR Successor Rate”), together with any proposed LIBOR Successor Rate  Conforming Changes.           If no LIBOR Successor Rate has been determined and the circumstances under clause (a)  above exist or the Scheduled Unavailability Date has occurred (as applicable), the Purchaser will  promptly  so  notify  the  Company.   Thereafter,  (x)  the  obligation  of  the  Purchaser  to  maintain  Eurodollar Rate Loans shall be suspended, (to the extent of the affected Eurodollar Rate Loans  or  Interest  Periods),  and  (y)  the  Eurodollar  Rate  component  shall  no  longer  be  utilized  in                                          3  

 

determining the Base Rate.  Upon receipt of such notice, the Company may revoke any pending  request for a conversion to or continuation of Eurodollar Rate Loans (to the extent of the affected  Eurodollar  Rate  Loans  or  Interest  Periods)  without  any  obligation  to  pay  any  loss,  cost  or  expense  of  Purchaser  pursuant  to  Section  9.3(a)  or,  failing  that,  will  be  deemed  to  have  converted such request into a request for a Base Rate Loans (subject to the foregoing clause (y))  in the amount specified therein.         Notwithstanding  anything  else  herein,  any  definition  of  LIBOR  Successor  Rate  shall  provide that in no event shall such LIBOR Successor Rate be less than zero for purposes of this  Agreement.         Section 3.  Ratification.  Except as expressly amended hereby, all of the provisions of  the Indenture shall remain unaltered and in full force and effect, and, as amended hereby, the  Indenture is in all respects agreed to, ratified and confirmed by the Issuer and the Trustee.  Any  holder of the Bonds, and all successive transferees of the Bonds, by accepting such Bond, are  deemed to have agreed to the terms of this Supplemental Indenture.         Section 4.  Severability.   In  the  event  any provision of this Supplemental Indenture  shall be held invalid or unenforceable by any court of competent jurisdiction, such holding shall  not invalidate or render unenforceable any other provision hereof.         Section 5.  Execution in Counterparts.  This Supplemental Indenture may be executed  in several counterparts, each of which shall be an original and all of which shall constitute but  one and the same instrument.         Section 6.    Applicable Law.  This Supplemental Indenture shall be governed by and  construed in accordance with the laws of the State of Mississippi.                                          4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]